Estrella Immunopharma (ESLAW) Competitors $0.09 0.00 (0.00%) (As of 12/13/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends ESLAW vs. ATNFW, SXTPW, DRTSW, WENAW, APLMW, BCTXW, CDIOW, CTCXW, CELUW, and CEROWShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Anew Medical (WENAW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Carmell (CTCXW), Celularity (CELUW), and CERo Therapeutics (CEROW). These companies are all part of the "biotechnology" industry. Estrella Immunopharma vs. 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical Anew Medical Apollomics BriaCell Therapeutics Cardio Diagnostics Carmell Celularity CERo Therapeutics 180 Life Sciences (NASDAQ:ATNFW) and Estrella Immunopharma (NASDAQ:ESLAW) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, community ranking, analyst recommendations and valuation. Does the MarketBeat Community believe in ATNFW or ESLAW? 180 Life Sciences and Estrella Immunopharma both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperform180 Life SciencesN/AN/AEstrella ImmunopharmaN/AN/A Does the media refer more to ATNFW or ESLAW? In the previous week, 180 Life Sciences and 180 Life Sciences both had 1 articles in the media. Estrella Immunopharma's average media sentiment score of 1.89 beat 180 Life Sciences' score of 1.87 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Overall Sentiment 180 Life Sciences Very Positive Estrella Immunopharma Very Positive Is ATNFW or ESLAW more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Estrella Immunopharma N/A N/A N/A Which has better earnings and valuation, ATNFW or ESLAW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/AEstrella ImmunopharmaN/AN/AN/AN/AN/A SummaryEstrella Immunopharma beats 180 Life Sciences on 1 of the 1 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most explosive phase of the cycle.>> Register for the Free WaveBot Workshop Now Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLAW and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLAW vs. The Competition Export to ExcelMetricEstrella ImmunopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$172.66M$5.27B$9.26BDividend YieldN/A3.51%5.17%3.99%P/E RatioN/A123.22100.1017.22Price / SalesN/A19,999.861,319.96150.35Price / CashN/A11.8642.8238.46Price / BookN/A8.244.884.88Net IncomeN/A-$19.55M$120.11M$225.60M7 Day PerformanceN/A223.77%17.75%-0.13%1 Month PerformanceN/A231.92%20.24%5.71%1 Year PerformanceN/A154.87%37.97%21.42% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAWEstrella ImmunopharmaN/A$0.09flatN/AN/A$0.00N/A0.00N/APositive NewsATNFW180 Life SciencesN/A$0.01-16.5%N/A+30.2%$0.00N/A0.007Gap DownSXTPW60 Degrees PharmaceuticalsN/A$0.02+0.7%N/A-22.0%$0.00$502,409.000.002Gap UpDRTSWAlpha Tau MedicalN/A$0.24+4.1%N/A+1.2%$0.00N/A0.0080Gap UpWENAWAnew MedicalN/A$0.04-0.3%N/AN/A$0.00N/A0.00N/AGap DownAPLMWApollomicsN/A$0.01-6.0%N/A-74.4%$0.00N/A0.0059Short Interest ↑BCTXWBriaCell TherapeuticsN/A$0.50+13.6%N/A-73.1%$0.00N/A0.008Short Interest ↑News CoverageHigh Trading VolumeCDIOWCardio DiagnosticsN/A$0.05-10.2%N/A+10.8%$0.00$35,688.000.007Short Interest ↓Gap DownHigh Trading VolumeCTCXWCarmellN/A$0.04+4.9%N/A-68.6%$0.00$32,839.000.009Gap UpCELUWCelularityN/A$0.02+31.2%N/A+120.6%$0.00$42.69M0.00220Gap UpCEROWCERo TherapeuticsN/A$0.01+30.6%N/AN/A$0.00N/A0.008Short Interest ↑Gap UpHigh Trading Volume Related Companies and Tools Related Companies 180 Life Sciences Competitors 60 Degrees Pharmaceuticals Competitors Alpha Tau Medical Competitors Anew Medical Competitors Apollomics Competitors BriaCell Therapeutics Competitors Cardio Diagnostics Competitors Carmell Competitors Celularity Competitors CERo Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ESLAW) was last updated on 12/14/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredThe War on Crypto is over …With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredWall Street Icon: “If you wait on this, it will already be too late”...Investing legend Louis Navellier warned us about the stock market crash of 1987... the 2000 dot-com crash… Enr...InvestorPlace | Sponsored$1 Trillion About to Get Wiped Out Because of this Sneaky Fed Move?The Federal Reserve is sitting on almost $1 TRILLION in unrealized losses. The reason why is that the Fed i...Behind the Markets | SponsoredA British Madness in AmericaWarren Buffett offloaded nearly 70% of his Apple holdings. They know, as I do, The Big AI Die Up is coming....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
